Navigation Links
Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/11/2008

r licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and our adjuvant in a timely manner; that enough HspE7 will be available to conduct our planned trials; that we will be able to procure the necessary amount of adjuvant to conduct our planned trials; that we will obtain timely approval from additional IRBs; that the results from additional preclinical and clinical work, if any, will be consistent with the results we have already obtained; that a sufficient number of patients will be available to conduct our planned trials; and that sufficient data will be generated to support our IND.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, including our 2006 Annual Information Form filed on SEDAR at http://www.sedar.com. Historical filings relating to the Company prior to the completion of the Company's March 23, 2006 corporate reorganization, including Old Stressgen's 2005 Annual Information Form dated March 16, 2006 may be reviewed on SEDAR at http://www.sedar.com under the SEDAR profile GVIC
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
5. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
8. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
9. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
10. Northwestern Memorial Transplant Program Initiates New Study
11. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- ReportsnReports.com adds Global Medical Simulation ... as well as Global Medical Simulation Market 2015-2019 ... of its library. Complete 2015 report ... across 164 pages, talking about 7 major companies ... now available at http://www.reportsnreports.com/reports/407046-global-medical-simulation-industry-report-2015.html . ...
(Date:8/3/2015)... 2015 Ortho Clinical Diagnostics (OCD) today announced ... Corporate Brand and Communications Officer, effective immediately. As the ... will lead the company,s worldwide corporate brand and communication ... an independent company by adding sites in countries outside ... Executive Officer Dr. Martin Madaus . ...
(Date:8/3/2015)... , August 3, 2015 ... is expected to reach USD 24.7 billion by ... View Research Inc. Growing prevalence of neurological and ... equipments market over the forecast period. The presence ... and cryotherapy, advancement in the technologies coupled with ...
Breaking Medicine Technology:Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
... MISSISSAUGA, Ontario, March 11, 2011 Valeant Pharmaceuticals ... VRX) announced that effective March 10, 2011, the ... S.A. About Valeant Valeant Pharmaceuticals ... pharmaceutical company that develops, manufactures and markets a ...
... (Nasdaq: OPTR ) today announced 2010 fourth quarter ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) Optimer reported a ... of $11.9 million, or $0.31 per common share, as compared ... common share, for the same period in 2009.  Optimer reported ...
Cached Medicine Technology:Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years of marital bliss ... on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas lead the non-denominational ... the ceremony was a reception, with music by the Moonlight Serenade Orchestra and a ...
(Date:8/4/2015)... ... August 04, 2015 , ... Dr. Gary Richter, ... America’s Favorite Veterinarian. The contest is put on by the American Veterinary Medical ... nominees. Nominees were evaluated on community involvement, ethical behavior, passion for profession, and ...
(Date:8/4/2015)... ... August 04, 2015 , ... The Law Offices ... medical device lawsuit claims dealing with Inferior Vena Cava Filters (“IVC Filters”). , As ... federal cases for Cook IVC Filter clients under In re Cook Medical, Inc., IVC ...
(Date:8/4/2015)... ... 04, 2015 , ... In the most recent talcum powder ... report that a new location for pretrial proceedings is under consideration, according to ... warning information at their website, the Talcum Powder Cancer Lawsuit Center. , The ...
(Date:8/4/2015)... ... August 04, 2015 , ... Continuing Education Company ... of an interaction simulation session entitled "NOACS: What the Evidence Shows in Managing ... Learning Institute Inc. and EDUmotion US LLC. , This special activity was recently ...
Breaking Medicine News(10 mins):Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3
... and Soothes Young Throats Now Available,Across the Northern ... cough and cold season,rapidly approaches, Integrated Beverage Group, ... products has launched its newest product,in Canada -- ... a perfect choice for parents who wish to,choose ...
... Company to Serve About 50,000 People Beginning February 1, ... AMERIGROUP,Corporation (NYSE: AGP ) announced today that the ... authorizing the Company,s Nevada subsidiary to,enter that State,s Medicaid ... 2009., The Nevada State Board of Examiners has ...
... lead to new treatments, researchers say , , WEDNESDAY, Nov. ... cells exhausted from fighting HIV infection has been discovered ... a molecule called Tim-3 is present at high levels ... HIV, the virus that causes AIDS. Blocking the activity ...
... Expertise to ... ... the,election of Jay Parsons to the company,s board of directors effective,immediately., ... programs and the development of customized incentive programs,that help consumers make ...
... likely to skip medicines, compared to whites , , WEDNESDAY, ... that included encouragement and occasional gifts improved medication adherence ... Americans with high blood pressure, a new study found. ... be nearly twice as likely to not take their ...
... That Demonstrate Best Strategic Use of Mergers ... ... Deal,( http://www.thedeal.com ) magazine has named Abbott,( http://www.abbott.com )as the healthcare ... honored Abbott for the,most effective strategic use of acquisitions and divestitures., ...
Cached Medicine News:Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 2Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 4Health News:Way to Rescue Tired Immune Cells Fighting HIV Found 2Health News:MedVantx(R) Names Newest Board Member 2Health News:Education Program Spurs Blacks to Take Blood Pressure Meds 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 3
... goniolaser lens features 4 precisely angled 64° ... of the anterior chamber angle with slight ... glass contact element) provides a stable platform ... 4 mirror lens provides a complete ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... The Chalam 45° Prism ... pathologies and are recommended for ... etc.) and Rhegmatogenus retinal detachment. ... panretinal photocoagulation and other midperipheral ...
... is specifically designed for internal ... hole surgery, optic nerve neurotomy, ... traditional macular edema and other ... lens was developed with K.V. ...
Medicine Products: